Abstract
Viral bronchiolitis continues to be a major public health problem. Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab. Development of more potent anti-RSV neutralizing antibodies is underway, and vaccine development continues to progress. Supportive therapy is the mainstay for the treatment of established infection while new antiviral and anti-inflammatory strategies are being explored in preclinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / therapeutic use
-
Bronchiolitis, Viral / diagnosis
-
Bronchiolitis, Viral / drug therapy
-
Bronchiolitis, Viral / prevention & control*
-
Child
-
Child, Preschool
-
Humans
-
Immunoglobulins / therapeutic use
-
Infant
-
Palivizumab
-
Paramyxoviridae Infections / prevention & control
-
Pediatrics / methods*
-
Pediatrics / trends*
-
Respiratory Syncytial Virus Infections / prevention & control
-
Viral Vaccines / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
Immunoglobulins
-
Viral Vaccines
-
Palivizumab